[1]王博,吴京,马明,等. 玻璃体内注射雷珠单抗与曲安奈德治疗糖尿病黄斑水肿的疗效对比分析[J].眼科新进展,2015,35(3):246-249.[doi:10.13389/j.cnki.rao.2015.0066]
　WANG Bo,WU Jing,MA Ming,et al. Clinictid effect comparison of intravitreal lucentis and triamcinolone acetonide for diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(3):246-249.[doi:10.13389/j.cnki.rao.2015.0066]
点击复制

 玻璃体内注射雷珠单抗与曲安奈德治疗糖尿病黄斑水肿的疗效对比分析
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
35卷
期数:
2015年3期
页码:
246-249
栏目:
应用研究
出版日期:
2015-03-05

文章信息/Info

Title:
 Clinictid effect comparison of intravitreal lucentis and triamcinolone acetonide for diabetic macular edema
作者:
 王博; 吴京; 马明; 李萍萍; 于健
 510515　广东省广州市，南方医科大学南方医院眼科
Author(s):
 WANG Bo ; WU Jing ;  MA Ming ;  LI Ping-Ping ; YU Jian
 Department of Ophthalmology , Nanfang Hospital of Southem Medical University, Guangzhou 5 105 15 , Guangdong Province , China
关键词:
 ; 糖尿病黄斑水肿; 雷珠单抗; 曲安奈德; 玻璃体内注射
Keywords:
 ; diabetic macular edema ; lucentis ;  triamcinolone acetonide ;  intravitreal injection
DOI:
10.13389/j.cnki.rao.2015.0066
文献标志码:
A
摘要:
 目的　对比分析玻璃体内注射雷珠单抗与曲安奈德治疗糖尿病黄斑水肿的临床疗效。方法　选取就诊于我院眼科的糖尿病黄斑水肿患者４７例（４８眼），病程６～１４个月；分为雷珠单抗组２４例２４眼，曲安奈德组２３例２４眼；分别给予玻璃体内注射雷珠单抗０．０５ｍＬ与曲安奈德０．０５ｍｇ，比较两组治疗１周、１个月、３个月、６个月患眼的最佳矫正视力、黄斑中心凹视网膜厚度、眼压及眼底黄斑区荧光素渗漏情况，观察治疗后的效果。结果　雷珠单抗组与曲安奈德组治疗后１周、１个月、３个月患眼的最佳矫正视力均得到提高，分别为０．０８±０.０２与０．０６±０．０３、０．２１±０．０３与０．１７±０．０５、０．２９±０．０７与０．２７±０．０４，治疗后短期内两组间差异无统计学意义（Ｐ值分别为０．０８２、０．０９２、０．３２０）；治疗６个月后，曲安奈德组患眼的最佳矫正视力（０．１８±０．０３）有５例出现回降现象；而雷珠单抗组患眼的最佳矫正视力（０．２８±０．０９）变化趋于稳定，两组间的差异有统计学意义（Ｐ＝０．００３）。治疗后１周、１个月、３个月、６个月雷珠单抗组与曲安奈德组患眼的黄斑中心凹视网膜厚度分别为（３３６．００±９４．７１）μｍ与（３７８．００±８９．７４）μｍ、（２５１．００±６３．５５）μｍ与（２７３．００±８１．２９）μｍ、（２６３.００±５９．４２）μｍ与（２６７．００±４９．３２）μｍ、（２３８．００±４２．６１）μｍ与（２９８．００±３３．２７）μｍ，治疗后各时间点两组间的差异均无统计学意义（Ｐ＝０．１２７、０．０７１、０．０５３、０．０５８）。另外，治疗后各时间点两组的眼压均在正常范围内，并且黄斑区荧光渗漏均无明显增强现象。结论　玻璃体内注射雷珠单抗和曲安奈德治疗糖尿病黄斑水肿，均能有效控制糖尿病视网膜病变患者病情发展并能改善视力。两种疗法的疗效在短期内差异无统计学意义，治疗６个月后，雷珠单抗疗效的稳定性优于曲安奈德。
Abstract:
 Objective To compare clinical effects of intravitreal lucentis ( LU ) and triamcinolone acetonide ( TA) for diabetic macular edema ( DME ). Methods Randomized controlled clinical retrospective study. Forty-seven patients ( 48 eyes) with DME in our hospital were chosen and divided into two groups , which were respectively intravitreal injected TA ( 0. 05 mg) and lucentis ( 0. 05 mL) . The duration was from 6 months t0 14 months. the changes of best corrected visual acuity ( BCVA) , central macular thickness ( CMT) .intraocular pressure and fundus fluorescein angiography ( FFA) in two groups at I week,l month,3 months and 6 months after treatment were compared between two groups, and clinical effects were observed. Results BCVA was improved in two groups at I week. I month ,3 months after treatment of lucentis and TA groups ,which were 0. 08 + 0. 02 and 0. 06 + 0. 03 .0. 21 + 0. 03 and 0. 17 + 0. 05 , 0. 29 + 0. 07 and 0. 27 + 0. 04 , respectively , there was no sigruficant difference ( P = 0. 082 ,0. 092 . 0. 320) . BCVA in TA group at 6 months after treatment was 0. 18 + 0. 03 .5 cases were decreased . while lucentis group kept stable vision acuity ( 0. 28 + 0. 09 ) , there was sigruficant difference(P = 0. 003) . CMT of lucentis group and TA group at I week.l month.3 months and 6 months after treatment were ( 336. 00 + 94. 71 ) ym and ( 378. 00 + 89. 74 ) ym , ( 251. 00 +63. 55 ) ym and ( 273. 00 +81. 29) ym , ( 263. 00 +59. 42) ym and ( 267. 00 + 49. 32 ) ym , ( 238. 00 + 42. 61 ) Vm and ( 298. 00 + 33. 27 ) Vm , respectively , there was no significant difference ( P = 0. 127 .0. 071 . 0. 053 , 0. 058 ) . A1l intraocular pressures were in the normal range and macular areas had no enhancing fluorescence leakage phenomenon after treatment in two groups. Conclusion Both intravitreal injection of lucentis and TA for DME can effectively control disease progression and improve visual acuity. Therapeutic effect is not significant between two methods in the short term . but after 6 months of treatment , the stability of lucentis is much better than that of TA.

相似文献/References:

[1]赵倩 金学民.Avastin联合黄斑格栅样光凝治疗糖尿病黄斑水肿的临床研究[J].眼科新进展,2013,33(2):000.
[2]沈强 张学东.糖尿病黄斑水肿的发病机制及治疗进展[J].眼科新进展,2012,32(2):000.
[3]赵勇 张卯年 任兵.激素缓释系统治疗糖尿病黄斑水肿新进展[J].眼科新进展,2012,32(10):000.
[4]曹薇 崔红平 张美萍.23G微切口玻璃体切割手术治疗糖尿病视网膜病变[J].眼科新进展,2013,33(11):000.
[5]刘平 苏胜. 白内障蛋白质组学研究的现状及未来研究方向[J].眼科新进展,2014,34(1):001.
[6]杨宝娣 宋艳萍 陈中山 丁琴. 微脉冲半导体激光对兔视网膜色素上皮细胞阈值下光凝的光生物调制效应[J].眼科新进展,2014,34(1):005.
[7]赖伟霞 梁皓 谭少健 李霞 邹文进 蒋林志. 钙调素在正常人及不同年龄白内障患者晶状体上皮细胞中的表达[J].眼科新进展,2014,34(1):010.
[8]郑燕林 刘聪慧 沙菽. 水蛭提取液对体外培养RF/6A的细胞液中MMP-2、IV型胶原含量的影响[J].眼科新进展,2014,34(1):013.
[9]周琨 高晓唯 蔡岩 李文静 胡裕坤 田丽丽 付燕. CCR7基因修饰的未成熟树突状细胞在大鼠高危角膜移植免疫排斥反应中的作用[J].眼科新进展,2014,34(1):017.
[10]高伟 程燕 吴洁 王亮 赵帅. 肉毒杆菌B诱导大鼠干眼模型中泪腺Lacritin蛋白表达的研究[J].眼科新进展,2014,34(1):021.
[11]徐浩,白宁艳,吕鹏,等. 雷珠单抗玻璃体内注射与黄斑部格栅样光凝联合治疗糖尿病性黄斑水肿的疗效观察[J].眼科新进展,2015,35(8):781.[doi:10.13389/j.cnki.rao.2015.0215]
　XU Hao,BAI Ning-Yan,LV Peng,et al. Intravitreous injection of ranibizumab combined with macular grid photocoagulation for diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(3):781.[doi:10.13389/j.cnki.rao.2015.0215]

备注/Memo

备注/Memo:
 广东省自然科学基金（编号：Ｓ２０１２０１０００８９４６、Ｓ２０１３０１００１６６４）
更新日期/Last Update: 2015-03-04